NuVasive (NUVA) continues to broaden its expandable portfolio with launch of the TLX® 20 degree expandable spinal interbody implant for transforaminal lumbar interbody fusion (TLIF).
Prior to TLX 20 receiving FDA 510(k) clearance in 4Q17, TLX interbodies were available in 15° lordotic options and only indicated for use with allograft. New levels include use in the thoracic spine and at the thoracolumbar junction to treat disc degeneration or degenerative spondylolisthesis at one or two adjacent levels. TLX 20 includes a single, low-profile instrument to position, expand and post-pack the implant with bone graft, improving visualization into the disc space and surgical workflow, according to NUVA.
TLX—which joins NUVA’s expandable interbody portfolio of MLX® and XLK® ACR— can be used with Integrated Global Alignment® (iGA) software for calculation of alignment parameters, pre-operatively.
Sources: NuVasive, Inc.; ORTHOWORLD Inc.